Cargando…

Cytogenetic and Genetic Abnormalities with Diagnostic Value in Myelodysplastic Syndromes (MDS): Focus on the Pre-Messenger RNA Splicing Process

Myelodysplastic syndromes (MDS) are considered to be diseases associated with splicing defects. A large number of genes involved in the pre-messenger RNA splicing process are mutated in MDS. Deletion of 5q and 7q are of diagnostic value, and those chromosome regions bear the numbers of splicing gene...

Descripción completa

Detalles Bibliográficos
Autores principales:	Douet-Guilbert, Nathalie, Soubise, Benoît, Bernard, Delphine G., Troadec, Marie-Bérengère
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320363/ https://www.ncbi.nlm.nih.gov/pubmed/35885562 http://dx.doi.org/10.3390/diagnostics12071658

Ejemplares similares

RBM22, a Key Player of Pre-mRNA Splicing and Gene Expression Regulation, Is Altered in Cancer
por: Soubise, Benoît, et al.
Publicado: (2022)

TP53 in Myelodysplastic Syndromes
por: Jiang, Yan, et al.
Publicado: (2021)

Asian Population Is More Prone to Develop High-Risk Myelodysplastic Syndrome, Concordantly with Their Propensity to Exhibit High-Risk Cytogenetic Aberrations
por: Jiang, Yan, et al.
Publicado: (2021)

Rare Cytogenetic Abnormalities in Myelodysplastic Syndromes
por: Bacher, Ulrike, et al.
Publicado: (2015)

Cytogenetic Abnormalities in Myelodysplastic Syndromes: An Overview
por: Zahid, Mohammad Faizan, et al.
Publicado: (2017)

Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions
por: Valent, Peter, et al.
Publicado: (2017)

Cytogenetic study in therapy-related myelodysplastic syndromes (t-MDS) and acute non-lymphocytic leukaemia (t-ANLL).
por: Sozzi, G., et al.
Publicado: (1990)

Human Cancer-Associated Mutations of SF3B1 Lead to a Splicing Modification of Its Own RNA
por: Bergot, Tiffany, et al.
Publicado: (2020)

Detailed analysis of clonal evolution and cytogenetic evolution patterns in patients with myelodysplastic syndromes (MDS) and related myeloid disorders
por: Schanz, Julie, et al.
Publicado: (2018)

Trisomy 8, a Cytogenetic Abnormality in Myelodysplastic Syndromes, Is Constitutional or Not?
por: Saumell, Sílvia, et al.
Publicado: (2015)

Defective control of pre–messenger RNA splicing in human disease
por: Chabot, Benoit, et al.
Publicado: (2016)

The Secondary Myelodysplastic Neoplasms (MDS) Jigsaw
por: Calvete, Oriol, et al.
Publicado: (2023)

Severe Eosinophilia in Myelodysplastic Syndrome With a Defined and Rare Cytogenetic Abnormality
por: Rai, Shinya, et al.
Publicado: (2019)

Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN
por: Mestrum, Stefan G. C., et al.
Publicado: (2020)

Standards and Impact of Hematopathology in Myelodysplastic Syndromes (MDS)
por: Valent, Peter, et al.
Publicado: (2010)

The role of azacitidine in the management of myelodysplastic syndromes (MDS)
por: Götze, KS, et al.
Publicado: (2009)

Assessing the Prognosis of Patients with Myelodysplastic Syndromes (MDS)
por: Kasprzak, Annika, et al.
Publicado: (2022)

ETV6-RUNX1 and RUNX1 directly regulate RAG1 expression: one more step in the understanding of childhood B-cell acute lymphoblastic leukemia leukemogenesis
por: Jakobczyk, Hélène, et al.
Publicado: (2021)

Cytogenetic features in myelodysplastic syndromes
por: Haase, Detlef
Publicado: (2008)

Using Bacterial Artificial Chromosomes in Leukemia Research: The Experience at the University Cytogenetics Laboratory in Brest, France
por: De Braekeleer, Etienne, et al.
Publicado: (2011)

Curcumin as an Epigenetic Therapeutic Agent in Myelodysplastic Syndromes (MDS)
por: Xie, Xiaoqing, et al.
Publicado: (2021)

Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)
por: Lucero, Josephine, et al.
Publicado: (2023)

Changed concepts and definitions of myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in the updated 2008 WHO classification
por: Hebeda, Konnie M., et al.
Publicado: (2009)

Clinical significance of cytogenetic and molecular genetic abnormalities in 634 Chinese patients with myelodysplastic syndromes
por: Yan, Xuefen, et al.
Publicado: (2021)

EHA Endorsement of the European Guidelines for Myelodysplastic Syndromes, MDS-RIGHT
por: Blum, Sabine, et al.
Publicado: (2021)

Molecular Drivers of Myelodysplastic Neoplasms (MDS)—Classification and Prognostic Relevance
por: Hoff, Fieke W., et al.
Publicado: (2023)

Iron overload in myelodysplastic syndromes (MDS) – diagnosis, management, and response criteria: a proposal of the Austrian MDS platform
por: Valent, P, et al.
Publicado: (2008)

Combining cytogenetic and epigenetic approaches in chronic lymphocytic leukemia improves prognosis prediction for patients with isolated 13q deletion
por: Bagacean, Cristina, et al.
Publicado: (2017)

Presence but not number of secondary type mutations influences outcome in de novo AML without MDS‐associated or recurring cytogenetic abnormalities
por: Weinberg, Olga K., et al.
Publicado: (2023)

FOXP1 and TP63 involvement in the progression of myelodysplastic syndrome with 5q- and additional cytogenetic abnormalities
por: L’Abbate, Alberto, et al.
Publicado: (2014)

Where are we with unintended effects in genome editing applications from DNA to phenotype: focus on plant applications
por: Troadec, Marie-Bérengère, et al.
Publicado: (2019)

Multi Cytogenetic Changes in a Patient as Co-Existing MDS and CLL Progresses
por: Li, Xiangxin, et al.
Publicado: (2021)

Cytogenetic features in primary myelodysplastic syndrome Egyptian patients
por: Elnahass, Yasser, et al.
Publicado: (2018)

Maitake mushroom extract in myelodysplastic syndromes (MDS): a phase II study
por: Wesa, Kathleen M., et al.
Publicado: (2014)

Perturbed hematopoietic stem and progenitor cell hierarchy in myelodysplastic syndromes patients with monosomy 7 as the sole cytogenetic abnormality
por: Dimitriou, Marios, et al.
Publicado: (2016)

Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective
por: de Witte, Theo, et al.
Publicado: (2020)

Age and cytogenetic abnormalities()
por: Souza, Cármino Antonio de
Publicado: (2018)

A case of myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) successfully treated with lenalidomide
por: Islam, Anwarul
Publicado: (2015)

Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS)
por: Yao, Chi-Yuan, et al.
Publicado: (2016)

Myelodysplastic Syndromes (MDS) & COVID-19: Clinical Experience from the US Epicenter of the Pandemic
por: Feld, Jonathan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2agi40kjdjpq9g60qf74nsank4